Loading…
Arbutus Biopharma Corporation is projected to rise to $4.78 by 2027, a +10% move from its current price of $4.34. ABUS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $4.24 | $4.34 | $4.44 | -0.03% |
| Aug 3 | $4.20 | $4.34 | $4.48 | -0.06% |
| Aug 4 | $4.17 | $4.34 | $4.51 | -0.09% |
| Aug 5 | $4.14 | $4.33 | $4.53 | -0.12% |
| Aug 6 | $4.12 | $4.33 | $4.56 | -0.15% |
| Aug 7 | $4.10 | $4.33 | $4.58 | -0.18% |
| Aug 8 | $4.08 | $4.33 | $4.60 | -0.22% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.08 | $4.33 | $4.60 | -0.22% |
| Week 2 | $3.97 | $4.32 | $4.70 | -0.43% |
| Week 3 | $3.89 | $4.31 | $4.78 | -0.64% |
| Week 4 | $3.82 | $4.30 | $4.84 | -0.86% |
| Week 5 | $3.76 | $4.29 | $4.90 | -1.07% |
| Week 6 | $3.71 | $4.28 | $4.95 | -1.28% |
| Week 7 | $3.65 | $4.28 | $5.00 | -1.50% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc.
to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Arbutus Biopharma Corporation trades in the Healthcare sector under the ticker ABUS. The current price is $4.41 and the market capitalization is $871.14M. Its market position includes a rank of 2488.
The year-by-year forecast provides an Avg price path from $4.41 in 2026 to $7.40 in 2030 and up to $30.51 by 2050, with corresponding max values reaching as high as $53.70 and ROIs climbing to 591.8%. The sentiment in the forecast moves from NEUTRAL in the near term to BULLISH in later years, reflecting an evolving long-term upside. The forecast shows a neutral stance in 2026, turning bullish in later years, notably from 2029 onward.
A major floor 15.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.2% away) — a key level to hold.
The nearest ceiling, 20.3% above — a clean break opens room to run.
A major ceiling 27.8% above — clearing it would confirm fresh momentum.
Key ABUS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ABUS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.37 | Sell | $4.37 | Sell |
| MA 10 | $4.40 | Sell | $4.43 | Sell |
| MA 20 | $4.62 | Sell | $4.50 | Sell |
| MA 50 | $4.52 | Sell | $4.51 | Sell |
| MA 100 | $4.45 | Sell | $4.47 | Sell |
| MA 200 | $4.45 | Sell | $4.34 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.47 | Neutral |
| Stoch RSI (14) | 21.53 | Neutral |
| CCI (20) | -78.94 | Neutral |
| Williams %R (14) | -88.89 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -4.82 | Sell |
| Bollinger %B (20,2) | 0.26 | Neutral |
| Stochastic %K (14) | 11.11 | Buy |
| TRIX (15) | -0.08 | Sell |
| Awesome (5,34) | -0.21 | Sell |
| Ultimate (7,14,28) | 46.93 | Neutral |
| Momentum (10) | -0.22 | Sell |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 4.34 | Sell |
| ADX (14) | 14.42 | Neutral |
| ATR (14) | 0.10 | Info |
The 30-day technical picture is NEUTRAL. RSI14 sits at 40, reflecting modest momentum.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.67 | $4.34 | $5.24 | 0% | Neutral | |
| $3.88 | $4.78 | $6.20 | +10% | Neutral | |
| $4.17 | $5.26 | $7.04 | +21% | Bullish | |
| $4.88 | $6.28 | $8.61 | +45% | Bullish | |
| $5.65 | $7.38 | $10.33 | +70% | Bullish | |
| $6.13 | $8.13 | $11.59 | +87% | Bullish | |
| $6.52 | $8.77 | $12.71 | +102% | Bullish | |
| $6.42 | $8.75 | $12.87 | +102% | Bullish | |
| $6.98 | $9.62 | $14.35 | +122% | Bullish | |
| $8.36 | $11.67 | $17.62 | +169% | Bullish | |
| $11.21 | $16.48 | $26.26 | +280% | Bullish | |
| $20.25 | $32.49 | $56.01 | +649% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.67 | $4.34 | $5.16 | +0.00% |
| September 2026 | $3.58 | $4.21 | $5.08 | -3.00% |
| October 2026 | $3.57 | $4.22 | $5.14 | +0.24% |
| November 2026 | $3.61 | $4.29 | $5.26 | +1.73% |
| December 2026 | $3.56 | $4.24 | $5.24 | -1.14% |
Click any year to see its month-by-month ABUS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ABUS is projected to trade between $3.67 and $5.24, averaging $4.34 — a potential gain of 0% from today's $4.34. Price action looks broadly range-bound.
Arbutus Biopharma Corporation's 2027 outlook centres on $4.78, within a $3.88 to $6.20 range. That is up +10% on the projected 2026 average. That marks a +10% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, ABUS could reach as high as $7.04, with a base case around $5.26 and support toward $4.17 — roughly +21% from $4.34. Momentum favours further upside here.
Expect ABUS to range from $4.88 to $8.61 through 2029. The $6.28 average target implies a +45% move from current prices. That is up +19% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The ABUS price prediction for 2030 points to an average of $7.38 (low $5.65, high $10.33) — a potential gain of +70% on today's $4.34. Momentum favours further upside here.
In 2031, ABUS is projected to trade between $6.13 and $11.59, averaging $8.13 — a potential gain of +87% from today's $4.34. That is up +10% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Arbutus Biopharma Corporation's 2032 outlook centres on $8.77, within a $6.52 to $12.71 range. That is up +8% on the projected 2031 average. That marks a +102% change versus current levels. Momentum favours further upside here.
By 2033, ABUS could reach as high as $12.87, with a base case around $8.75 and support toward $6.42 — roughly +102% from $4.34. Buyers look set to stay in control over this stretch.
Expect ABUS to range from $6.98 to $14.35 through 2034. The $9.62 average target implies a +122% move from current prices. That is up +10% on the projected 2033 average. Momentum favours further upside here.
The ABUS price prediction for 2035 points to an average of $11.67 (low $8.36, high $17.62) — a potential gain of +169% on today's $4.34. Buyers look set to stay in control over this stretch.
In 2040, ABUS is projected to trade between $11.21 and $26.26, averaging $16.48 — a potential gain of +280% from today's $4.34. That is up +41% on the projected 2035 average. Momentum favours further upside here.
Arbutus Biopharma Corporation's 2050 outlook centres on $32.49, within a $20.25 to $56.01 range. That is up +97% on the projected 2040 average. That marks a +649% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in ABUS today (≈ 230.414747 ABUS) could be worth
$7,485.67
+$6,485.67 (+649%) by 2050 · US Dollar
Based on the average projected ABUS price of $32.49 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ABUSwould be worth at today's price.
$1,000 invested in ABUS on Jul 31, 2025 (≈ 304.878051 ABUS) would be worth
$1,323.17
+$323.17 (+32.3%) today · 1.32× · US Dollar
Based on a ABUS entry price of $3.28 vs. today's $4.34.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.38 | $990.87 | -0.9% |
| 1 month ago | $4.73 | $917.55 | -8.2% |
| 3 months ago | $4.32 | $1,004.63 | +0.5% |
| 6 months ago | $4.39 | $988.61 | -1.1% |
| 1 year ago | $3.28 | $1,323.17 | +32.3% |
| All time (5.0y) ago | $2.71 | $1,601.48 | +60.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ABUS forecast.
Our base-case forecast reaches $8.70 around 2032.
Implied market cap at $8.70: $1.72B
The multi-year forecast shows a gradual shift from neutral to bullish over time. In 2026 the avg price is $4.41 with 0% ROI, followed by 2027 at $4.85 (ROI 9.9) and 2028 at $5.23 (ROI 18.7). In 2029 the avg is $6.15 (ROI 39.4) and by 2030 the avg reaches $7.40 (ROI 67.7).
The trajectory continues to 2040 with an avg of $15.67 (ROI 255.4) and then 2050 with an avg of $30.51 (ROI 591.8). These are estimates, not guarantees. The sentiment in the forecast becomes BULLISH from 2029 onward, signaling higher upside potential while acknowledging inherent uncertainty and risk.
Tap a question to reveal the answer.
Avg $7.40, min $5.61, max $10.47, ROI 67.7%, sentiment BULLISH.
The forecast shows a path to rising values with 2030 avg $7.40 and ROI 67.7% and 2050 avg $30.51 with ROI 591.8%. These are estimates, not guarantees, and carry inherent market risks.
Yes—the forecast max for 2030 is $10.47, with higher highs in later years (2040 max $25.41, 2050 max $53.70).
Current price is $4.41 and market cap is $871.14M.
The 30-day range is $3.77 to $5.16.
Arbutus Biopharma Corporation Community Discussion
0Share your Arbutus Biopharma Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.